Related references
Note: Only part of the references are listed.Prevention of Esophageal Stricture After Endoscopic Submucosal Dissection Using Tissue-Engineered Cell Sheets
Takeshi Ohki et al.
GASTROENTEROLOGY (2012)
Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case
Yoshiki Sawa et al.
SURGERY TODAY (2012)
Efficacy and Safety of Long-term Prophylaxis in Severe Hemophilia A Dogs Following Liver Gene Therapy Using AAV Vectors
Denise E. Sabatino et al.
MOLECULAR THERAPY (2011)
Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B
Amit C. Nathwani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Reversal of Diabetes by the Creation of Neo-Islet Tissues Into a Subcutaneous Site Using Islet Cell Sheets
Takahiro Saito et al.
TRANSPLANTATION (2011)
Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B
Valder R. Arruda et al.
BLOOD (2010)
Validation of human periodontal ligament-derived cells as a reliable source for cytotherapeutic use
Takanori Iwata et al.
JOURNAL OF CLINICAL PERIODONTOLOGY (2010)
Safety of AAV Factor IX Peripheral Transvenular Gene Delivery to Muscle in Hemophilia B Dogs
Virginia Haurigot et al.
MOLECULAR THERAPY (2010)
Reconstruction of functional tissues with cell sheet engineering
Joseph Yang et al.
BIOMATERIALS (2007)
Engineering functional two- and three-dimensional liver systems in vivo using hepatic tissue sheets
Kazuo Ohashi et al.
NATURE MEDICINE (2007)
Surface characterization of poly(N-isopropylacrylamide) grafted tissue culture polystyrene by electron beam irradiation, using atomic force microscopy, and X-ray photoelectron spectroscopy
Yoshikatsu Akiyama et al.
JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY (2007)
Ex vivo gene therapy for hemophilia a that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors
Hideto Matsui et al.
STEM CELLS (2007)
Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs
HY Jiang et al.
BLOOD (2006)
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration
Eugenio Montini et al.
NATURE BIOTECHNOLOGY (2006)
Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1
MG Ott et al.
NATURE MEDICINE (2006)
Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response
CS Manno et al.
NATURE MEDICINE (2006)
In vivo engineering of metabolically active hepatic tissues in a neovascularized subcutaneous cavity
T Yokoyama et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Clinical gene transfer studies for hemophilia A
MKL Chuah et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2004)
Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A
BD Brown et al.
BLOOD (2004)
Corneal reconstruction with tissue-engineered cell sheets composed of autologous oral mucosal epithelium
K Nishida et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
S Hacein-Bey-Abina et al.
SCIENCE (2003)
Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion
JS Powell et al.
BLOOD (2003)
Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors
MKL Chuah et al.
BLOOD (2003)
Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
DA Roth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
